Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Jaakko Tuomilehto,
Dr. Michael Lehrke (Aachen, Germany) pointed out the high risk of cardiovascular diseases (CVD) in type 2 diabetic (T2D) patients, and that the risk increases with increasing glycaemia, measured by HbA1c. The main question is: to what extent this excess risk can be reduced by treatments lowering glycaemia. Recent trials have pointed out that intensive glucose lowering treatment may lead to hypoglycaemic events and these can be dangerous causing vascular events and even deaths. A recent meta-analysis of controlled trials indicated a 10% and 15% reduction in all MIs and in non-fatal MI, respectively. NNT to prevent one MI with glucose lowering treatment is 140 patients/5years. For cholesterol lowering it is 44 and blood pressure lowering 34. It seems that there is no benefit to lower HbA1c below 7.5%, actually mortality starts to increase at lower levels. On the other hand, in non-diabetic people “ideal” HbA1c is around 5.3%, and in T2D the greatest benefits are seen in those whose baseline HbA1c is <7.5%. Also, patients who are free of CVD benefit more from glucose lowering than those with CVD . With comorbidities, life expectance is dramatically reduced. Therefore, it is important to apply individualized glucose lowering therapy, and combine it with multifactorial risk reduction strategy. Reducing excess body weight as early as possible is very important; antidiabetic drug therapy often represents an attempt to compensate the failure of restriction of excess energy intake. With modern new antidiabetic drugs, treatment can be rather expensive, too.
ESC/EAS guidelines for treatment of dyslipidaemia in diabetes have just been published (Eur Heart J 2011;32:1769): LDL goal in high-risk T2D patient is <1.8 mmol/L, all T2D <2.5 mmol/L and T1D >30% reduction. Statin therapy is the basis, fibrates do not improve the prognosis. Aspirin should be used with care, paying attention to the risk of bleeding, and not used on every T2D patient.
Controversial issues in diabetes management
© 2017 European Society of Cardiology. All rights reserved